FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310020061> ?p ?o ?g. }

• W4310020061 endingPage "20" @default.
• W4310020061 startingPage "20" @default.
• W4310020061 abstract "The characterization of the molecular profile in acute myeloid leukemia (AML) is essential for diagnosis, prognosis, risk stratification and therapeutic management. The aims of this study were: 1) To evaluate the molecular profile of patients with acute myeloid leukemia in a clinical laboratory at diagnosis and 2) To evaluate the sensitivity of different strategies for detection of FLT3 ITD mutation. We included 118 patients with a diagnosis of acute AML from March 2018 to December 2021 from a single diagnostic center. After extraction of DNA from peripheral blood or bone marrow samples were subjected to library preparation according to the Illumina Trusight Myeloid Sequence Panel, sequenced in a NextSeq550 (Illumina) and processed in a bioinformatic pipeline that used the following variant callers: Mutec1, Mutect2, Freebayes and Pindel. In addition we used ITDSeq for FLT3 ITD detection. Of the samples analyzed, 86.4% (102/118) presented clinically relevant variants. The most frequently mutated genes were FLT3 (26.4%), DNMT3A (24.5%), ASXL1 (16.7%), SRSF2 (14.7%), TP53 (12.7%), NPM1 (12,7%), TET2 (10.8%), NRAS (10.8%) and IDH2 (10.8%). Of 24 samples harboring FLT3-ITD mutation detected by capillary electrophoresis, our bioinformatics pipeline detected 83%, and the algorithm ITDseek also detected 83% of the mutations. When both strategies were combined, the detection rate was 95%. In one case, the only positive method was capillary electrophoresis. The data obtained reinforce the need to include panels like this in the diagnostic routine and reveal the importance of complementary analysis of the FLT3-ITD mutation by capillary electrophoresis. The characterization of the molecular profile in acute myeloid leukemia (AML) is essential for diagnosis, prognosis, risk stratification and therapeutic management. The aims of this study were: 1) To evaluate the molecular profile of patients with acute myeloid leukemia in a clinical laboratory at diagnosis and 2) To evaluate the sensitivity of different strategies for detection of FLT3 ITD mutation. We included 118 patients with a diagnosis of acute AML from March 2018 to December 2021 from a single diagnostic center. After extraction of DNA from peripheral blood or bone marrow samples were subjected to library preparation according to the Illumina Trusight Myeloid Sequence Panel, sequenced in a NextSeq550 (Illumina) and processed in a bioinformatic pipeline that used the following variant callers: Mutec1, Mutect2, Freebayes and Pindel. In addition we used ITDSeq for FLT3 ITD detection. Of the samples analyzed, 86.4% (102/118) presented clinically relevant variants. The most frequently mutated genes were FLT3 (26.4%), DNMT3A (24.5%), ASXL1 (16.7%), SRSF2 (14.7%), TP53 (12.7%), NPM1 (12,7%), TET2 (10.8%), NRAS (10.8%) and IDH2 (10.8%). Of 24 samples harboring FLT3-ITD mutation detected by capillary electrophoresis, our bioinformatics pipeline detected 83%, and the algorithm ITDseek also detected 83% of the mutations. When both strategies were combined, the detection rate was 95%. In one case, the only positive method was capillary electrophoresis. The data obtained reinforce the need to include panels like this in the diagnostic routine and reveal the importance of complementary analysis of the FLT3-ITD mutation by capillary electrophoresis." @default.
• W4310020061 created "2022-11-30" @default.
• W4310020061 creator A5004714158 @default.
• W4310020061 creator A5012460330 @default.
• W4310020061 creator A5017588406 @default.
• W4310020061 creator A5028939963 @default.
• W4310020061 creator A5042047372 @default.
• W4310020061 creator A5071605487 @default.
• W4310020061 date "2022-11-01" @default.
• W4310020061 modified "2023-09-27" @default.
• W4310020061 title "62. Molecular profile of patients with Acute Myeloid Leukemia at diagnosis" @default.
• W4310020061 doi "https://doi.org/10.1016/j.cancergen.2022.10.065" @default.
• W4310020061 hasPublicationYear "2022" @default.
• W4310020061 type Work @default.
• W4310020061 citedByCount "0" @default.
• W4310020061 crossrefType "journal-article" @default.
• W4310020061 hasAuthorship W4310020061A5004714158 @default.
• W4310020061 hasAuthorship W4310020061A5012460330 @default.
• W4310020061 hasAuthorship W4310020061A5017588406 @default.
• W4310020061 hasAuthorship W4310020061A5028939963 @default.
• W4310020061 hasAuthorship W4310020061A5042047372 @default.
• W4310020061 hasAuthorship W4310020061A5071605487 @default.
• W4310020061 hasConcept C104317684 @default.
• W4310020061 hasConcept C121608353 @default.
• W4310020061 hasConcept C126322002 @default.
• W4310020061 hasConcept C143998085 @default.
• W4310020061 hasConcept C21790070 @default.
• W4310020061 hasConcept C2483381 @default.
• W4310020061 hasConcept C2778729363 @default.
• W4310020061 hasConcept C2779282312 @default.
• W4310020061 hasConcept C2780007613 @default.
• W4310020061 hasConcept C2781187634 @default.
• W4310020061 hasConcept C30481170 @default.
• W4310020061 hasConcept C502942594 @default.
• W4310020061 hasConcept C526805850 @default.
• W4310020061 hasConcept C53226629 @default.
• W4310020061 hasConcept C54355233 @default.
• W4310020061 hasConcept C60644358 @default.
• W4310020061 hasConcept C70721500 @default.
• W4310020061 hasConcept C71924100 @default.
• W4310020061 hasConcept C86803240 @default.
• W4310020061 hasConceptScore W4310020061C104317684 @default.
• W4310020061 hasConceptScore W4310020061C121608353 @default.
• W4310020061 hasConceptScore W4310020061C126322002 @default.
• W4310020061 hasConceptScore W4310020061C143998085 @default.
• W4310020061 hasConceptScore W4310020061C21790070 @default.
• W4310020061 hasConceptScore W4310020061C2483381 @default.
• W4310020061 hasConceptScore W4310020061C2778729363 @default.
• W4310020061 hasConceptScore W4310020061C2779282312 @default.
• W4310020061 hasConceptScore W4310020061C2780007613 @default.
• W4310020061 hasConceptScore W4310020061C2781187634 @default.
• W4310020061 hasConceptScore W4310020061C30481170 @default.
• W4310020061 hasConceptScore W4310020061C502942594 @default.
• W4310020061 hasConceptScore W4310020061C526805850 @default.
• W4310020061 hasConceptScore W4310020061C53226629 @default.
• W4310020061 hasConceptScore W4310020061C54355233 @default.
• W4310020061 hasConceptScore W4310020061C60644358 @default.
• W4310020061 hasConceptScore W4310020061C70721500 @default.
• W4310020061 hasConceptScore W4310020061C71924100 @default.
• W4310020061 hasConceptScore W4310020061C86803240 @default.
• W4310020061 hasLocation W43100200611 @default.
• W4310020061 hasOpenAccess W4310020061 @default.
• W4310020061 hasPrimaryLocation W43100200611 @default.
• W4310020061 hasRelatedWork W1973321908 @default.
• W4310020061 hasRelatedWork W1998001202 @default.
• W4310020061 hasRelatedWork W2034581480 @default.
• W4310020061 hasRelatedWork W2115695360 @default.
• W4310020061 hasRelatedWork W3009206022 @default.
• W4310020061 hasRelatedWork W3031545866 @default.
• W4310020061 hasRelatedWork W3168030943 @default.
• W4310020061 hasRelatedWork W3206858243 @default.
• W4310020061 hasRelatedWork W4310020061 @default.
• W4310020061 hasRelatedWork W4319461823 @default.
• W4310020061 hasVolume "268-269" @default.
• W4310020061 isParatext "false" @default.
• W4310020061 isRetracted "false" @default.
• W4310020061 workType "article" @default.